Sodium Chloride 0.9% w/v. Nasal drops, 20 ml
2 drops in each nostril up to 4 times/d.
For the relief of nasal congestion in children and infants
C/I: hypersens.
peroxisome proliferator-activated receptor delta (PPARδ) agonist. Seladelpar 10 mg. Caps: 30 X 10 mg
Recomm. dose: 10 mg once daily.
For prim. biliary cholangitis (PBC) in combin. with ursodeoxycholic acid (UDCA) in adlts who have an inadequate resp. to UDCA alone, or as monother. in those unable to toler. UDCA.
C/I: Hypersens.
Antivirals. Bulevirtide 2 mg/ml. Vial. Pwder. for sol. for inj. 30 X 2 mg
Manage the underlying hepatitis B virus (HBV) infect. simultan. according to the official guidelines. To be admin. 1/d by SC inject. Recomm. dosage is 2 mg 1/d as long as clin. benef. is seen.
Tmt.of chronic hepatitis delta virus (HDV) infect. in plasma (or serum) HDV-RNA posit. adults with compensated liver dis.
C/I: Hypersens.
Drug class Cross-linked polyacrylic acid sodium salt, hydroxy propyl
methyl cellulose (HPMC), titanium dioxide, cellulose acetate
phthalate, hydroxypropyl cellulose, chitosan, diethyl
phthalate, polyvinyl alcohol polyethylene copolymer
(Kollicoat), triethyl citrate, cellulose acetate, acetyl tributyl
citrate.
Caps. X 56
1 cap. before meal X 2/d
Reducing BW in pts with 25 < BMI < 40 in conjunction with diet and exercise.
C/I: Hypersens. Pregn
Corticosteroid. Budesonide 2 mg. Canister with 14 X of 1.2 g
One actuation of 2 mg /d
Tmt of act. ulcerative colitis limited to the rectum and the sigmoid colon
C/I: Hypersens. /hepatic cyrrhosis
Anti-CD20, Human Monoclonal Antibody. Ocrelizumab 40 mg/ml. Vial. 1 X 920 mg for SC inject.
single 23 mL in the abdomen over approx. 10 minutes every 6 months.
For adults with relapsing or primary progress. forms of multiple sclerosis.
C/I:Hypersens. Active HBV infection/ A hist. of life-threatening admin. reaction to ocrelizumab
ההשפעות האנטי-פיברוטיות של טיפולים תרופתיים חדשים לאי-ספיקת לב בחולים עם אי-ספיקת לב מתקדמת
כלי הדמיה אמין לרדיותרפיה בסרטן הרקטום: דימות מונו-אנרגטי וירטואלי
יעילות חיסון אימהי ב-Tdap5 למניעת שעלת בתינוקות
תיאור מקרה והשלכות כירורגיות: כיס מרה שמאלי ללא היפוך איברים
השפעת מעכבי SGLT2 ו-GLP1 על הסיכון לקטרקט בחולי סוכרת
למידת מכונה חושפת גורמים המשפיעים על תוצאי סרטן גלובליים
חסימת סימפונות ברונכוסקופית לעצירת דימום ריאתי בתינוק
תוצאות מבטיחות להחלפת מפרק ירך מסוג קרמיקה-על-קרמיקה
לעלון לצרכן לחצו כאן
הודעה על עדכון בעלון של התכשירים:
Cresemba 100 mg Capsules - לפרטים נוספים לחץ כאן
Cresemba 200 mg IV - לפרטים נוספים לחץ כאן
Ixifi - לפרטים נוספים לחץ כאן
Xanax X.R - לפרטים נוספים לחץ כאן
Diflucan 50mg/ml-לפרטים נוספים לחצו כאן
Trican 200 mg-לפרטים נוספים לחצו כאן
Triflucan I.V-לפרטים נוספים לחצו כאן
IXIFI-לפרטים נוספים לחצו כאן
Monoclonal Antibody. Eculizumab 10 mg/ml. VIAL (concentrate for sol. for infus.): 1×300mg. Adult. (≥18 years of age): (PNH)-consists of a 4-week initial phase follow. by a mainten. phase: Initial phase: 600 mg admin. via a 25–45 min. IV infus. every wk. for the first 4 wks.
Mainten. phase: 900 mg admin. via a 25-45 min. IV infus. for the 5TH week, follow. by 900 mg admin. via a 25–45 min. IV infus. every 14±2 d.
In atyp. Haemolytic Uremic Synd. (aHUS) and refract. general. Myasthenia Gravis (gMG): The aHUS and refract. gMG dosing regimen for adult pts. (≥18 yrs. of age) consists of a 4 wk. init. phase follow. by a mainten. phase: Init. phase: 900 mg admin. via a 25–45 min. IV infus. every wk. for the first 4 wks.
Mainten. phase: 1,200 mg admin. via a 25–45 min. IV infus. for the fifth wk., follow. by 1,200 mg admin. via a 25–45 min. IV infus. every 14±2 d.
Paed. pts. in PNH and aHUS: Paed. pts PNH, above 11 yrs. old, and aHUS pts. with bdy. wt.≥40 kg are treated with the adult dosing recommend. respectively.
Pts. bdy. wt. 30 to<40 kg init. phase 600 mg wkly.×2, mainten. phase 900 mg at wk. 3; then 900 mg every 2 wks.
Pts. bdy. wt. 20 to<30 kg, init. phase 600 mg wkly.×2, mainten. phase 600 mg at wk. 3; then 600 mg every 2 wks.
Pts. bdy. wt. 10 to<20 kg, init. phase 600 mg wkly.×1, mainten. phase 300 mg at wk. 2; then 300 mg every 2 wks.
Pts. bdy. wt. 5 to<10 kg, init. phase 300 mg wkly.×1 mainten. phase 300 mg at wk. 2; then 300 mg every 3 wks. See lit.
Paroxysmal nocturnal haemoglobinuria (PNH).
Evidence of clinical benefit is demonstrat. in pts. with haemolysis with clinical sympt. indicative of high dis. activity, regardless of transfus. history.
Eculizumab has not been studied in clinic. trials in pts. with PNH below 11 yrs. of age.
Atypical haemolytic uremic syndr. (aHUS).
Soliris is indicated in adult. for the tmt. of: Refract. generalized myasthenia gravis (gMG) in pts. who are anti-acetylcholine receptor (AChR) antibody-positive.
C/I: Hypersens. Therapy must not be init. in pts.: with unresolved Neisseria meningitidis infect, pts. that are not current. vaccine. against Neisseria meningitidis unless they receive prophylact. tmt. with appropr. antibiot. until 2 wks. after vaccinat.
Corticosteroid, Vitamin D Analogue. Betamethasone (as dipropionate) 0.5 mg/g, Calcipotriol (as monohydrate) 50 mcg/g. ALUMINIUM CAN:60 g.
Enstilar foam should be applied to the affected area once dly. The recom. tmt. period is 4 wks. The dly. max. dose should not exceed 15 g, i.e. one 60 g can should last for at least 4 d. 15 g corresponds to the amount admin. from the can if the actuator is fully depressed for approx. one minute. A two-second application delivers approx. 0.5 g. As a guide, 0.5 g of foam should cover an area of skin roughly correspond. to the surface area of an adult hand. Concomit. use with other topic. products contain. calcipotriol in addition to Enstilar: the total dose of all calcipotriol contain. products should not exceed 15 g/d. The total bdy. surf. area treated should not exceed 30%.
Ren. / hep. impair. The safety and efficacy in pts. with severe renal insuffic. or severe Hep. disord. have not been evaluated.
Ped. population:The safety and efficacy in child. below 18 yrs. have not been establish. Enstilar is not indic. for child<18 yrs. of age.
Topical tmt. of psoriasis vulgaris in adults.
C/I: Hypersens.
Pts. with erythrodermic and pustular psorias.
Pts. with known calcium metabolism disord.
Monobenzone Like Depigmentation Agent. Hydroquinone 4%. GEL: 60 g. Start with 1 applic. a day for
10-15 d. on skin spots and contin. with
2 x dly morn. and even.
Lighten. skin spots.
C/I: Child. under 12 yrs., tmt. of
hyperpigmentat. resulted from chemic.
ochronosis & degeneration colloid
(colloid milium) both from employment
as cosmet.
Neurokinin 3 Receptor Antagonist. fezolinetant 45 mg. FC tabs. 30 X 45 mg
45 mg once daily. See lit.
tmt. of moder. to sev. vasomotor sympt. (VMS) assoc. with menopause.
C/I: Hypersens. Concom. use of moder. or strong CYP1A2 inhibit.
Known or suspect. pregn.
Moder. or sev. hepat. impairm. (Child Pugh B or C).
CCB, Local Anesthetic. Lidocaine HCl 1.5%, Nifedipine 0.3%. RECTAL CR.: 30g. Should be applied twice dly. for at least 3 wks. See lit.
Tmt. of anal fissures and proctolog. general. associate. with anal sphincter hypertonia.
C/I: Hypersens. to the active ingred., partic. to Lidocaine (& other local anesthet. with a similar amidic type structure). Presumed or ascertained preg. & lact.
Histamine H1 Antagonist 2nd Generation. Bilastine 20 mg. TABS.: 20 mg. Adult. and adolesc. (12 yrs. of age and over) 1 tab×1/d for the relief of sympt. of allergic rhino-conjunctivit. (SAR and PAR) and urticaria. The tab. should be taken 1/2h. before after intake of food or fruit juice.
Indic. the symptom. tmt. of allerg. rhino-conjunctiv. (season. and perenn.) and urticaria in adult. and adolesc.(12 yrs. of age and over).
C/I: Hypersens.
Urinary Antispasmodic. Mirabegron 25 mg, 50 mg. PROLONG REL. TABS.: 30×25, 50 mg.
Adult. (include. elder. pts.) 50 mg once
daily with/without food.
Sympt. tmt. of urgency, incr. micturition
freq. and/or urgency incont. as may occur
in adult pts. with OAB syndr.
C/I: Hypersens.
Nicotine Receptor Partial Agonist. Varenicline (as tartrate) 0.5 mg, 1 mg. Health basket inclusion: Champix will be given to the treatment of smoking cessation parallel to supportive means.
TABS: 55 x 0.5 mg, 56 x 1 mg; starter pack: 11 x 0.5 mg + 14, 28 x 1 mg.
Days 1 – 3: 0.5 mg ×1/d.
Days 4– 7: 0.5 mg ×2/d.
Day 8 – end of tmt.: 1 mg ×2/d.
Pts. should be treated with Varenicline for 12 wks. For pts. who have successf. stopped smok. at the end of 12 wks., an addit. course of 12 wks. tmt. with Varenicline is recomm. to further incr. the likelihood of long-term abstinence.
Pts. with ren. impair. No dosage adjust. is necessary for pts. with mild- moder. renal impair. For pts. with sev. renal impair. (estimated CrCl <30 mL/min), the recomm. start. dose of Varenicline is 0.5 mg ×1/d. The dose may then be titrated as needed to a max. dose of 0.5 mg×2/d. For pts. with end-stage renal dis. underg. hemodialysis, a max. dose of 0.5 mg mg×/d may be admin. if toler.
Aid to smoking cessat. for adults over 18
yrs.
C/I: Hypersens., known skin react. to varenicline
Antihistamine, Decongestant. Loratadine 5 mg, Pseudoephedrine Sulphate 120 mg. TABS: 14. One tab. ×2/d with a glass of water. The durat. of tmt. should be kept as short as possible. It is advisable to limit tmt. to about 10 d.
Relief of sympt. of season. allerg. rhinitis when both the antihistam. properties and the nasal decongest. activity are desired.
C/I: Hypersens. Pts. who are receiv. irrevers. MAO inhib. ther. or during the 2 wks. follow. the stop. of such tmt., and in pts. with: narrow-ang. glauc., urin.retent., cardiovasc. dis. (e.g. ischaem. heart dis., tachyarrhythm. sev. hypertens. hyperthyroid)., Pts. with hist. of haemorhag. stroke or with risk fact. which could incr. the risk of haemorhag. stroke (in comb. with other vasoconstrict. such as bromocripitine, pergolide, lisuride, cabergoline, ergotamine, dihydroergotamine or any other decongest. meds. used as a nasal decongest., either by oral route or by nasal route, e.g. phenylpropanolamine, phenylephrine, ephedrine, oxymetazoline, naphazoline).
